For research use only. Not for therapeutic Use.
Disitamab vedotin（Cat No.:I044207）is an antibody-drug conjugate (ADC) composed of a humanized anti-HER2 monoclonal antibody (disitamab) linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a cleavable linker. It selectively targets HER2-overexpressing tumor cells, delivering MMAE intracellularly to disrupt microtubule formation and induce apoptosis. Unlike trastuzumab, disitamab exhibits broader binding to HER2-expressing tumors, including those with low to moderate expression. Disitamab vedotin is being evaluated in clinical trials for various HER2-positive and HER2-low cancers, including breast, gastric, and urothelial cancers, offering promise as a targeted cancer therapy.
| CAS Number | 2136633-23-1 |
| Purity | ≥95% |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
